During T2DM treatment, metformin reduces circulating glucose and insulin levels via a blockage of gluconeogenesis in the liver and via improvement of peripheral insulin sensitivity by opposing the action of glucagon, increasing glucose uptake in the muscle while decreasing glucose absorption in the small intestine, and inhibiting lipolysis in adipose tissue [[13], [14], [15], [16]]. This evidence concerns the gene INS and type 2 diabetes mellitus.